BL-S786 (Ceforanide), a New Parenteral Cephalosporin: In Vitro Studies
AUTOR(ES)
Weaver, Susanne S.
RESUMO
BL-S786 (ceforanide) is a new cephalosporin which showed broad-spectrum activity in vitro against 453 clinical isolates. At a concentration of 3.12 μg/ml, it inhibited greater than 75% of isolates of Escherichia coli, Klebsiella spp., Proteus mirabilis, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae. Essentially no activity was observed against isolates of Serratia marcescens, and only minimal activity was observed against Enterobacter spp. Its activity was directly related to the size of the inoculum. The minimal bactericidal concentrations were similar to the minimal inhibitory concentrations for isolates of all organisms except S. aureus and S. pyogenes. The minimal bactericidal concentrations were considerably higher than the minimal inhibitory concentrations for these organisms.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=352652Documentos Relacionados
- Cefazaflur, a New Parenteral Cephalosporin: In Vitro Studies
- In Vitro Activity and Beta-Lactamase Stability of BL-S786 Compared with Those of Other Cephalosporins
- In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole.
- In Vitro Evaluation of a New Oral Cephalosporin, Cefatrizine (BL-S640)
- Comparative Pharmacokinetics of Ceforanide (BL-S786R) and Cefazolin in Laboratory Animals and Humans
